1,788 Shares in Humana Inc. (NYSE:HUM) Purchased by Gladius Capital Management LP

Gladius Capital Management LP purchased a new stake in Humana Inc. (NYSE:HUMGet Rating) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,788 shares of the insurance provider’s stock, valued at approximately $830,000. Humana makes up about 0.1% of Gladius Capital Management LP’s portfolio, making the stock its 24th largest position.

A number of other institutional investors have also recently bought and sold shares of the business. Wellington Management Group LLP raised its holdings in Humana by 10.7% in the 3rd quarter. Wellington Management Group LLP now owns 6,465,032 shares of the insurance provider’s stock valued at $2,515,867,000 after acquiring an additional 626,652 shares in the last quarter. Viking Global Investors LP raised its holdings in Humana by 411.2% in the 3rd quarter. Viking Global Investors LP now owns 3,007,133 shares of the insurance provider’s stock valued at $1,170,226,000 after acquiring an additional 2,418,848 shares in the last quarter. Capital Research Global Investors raised its holdings in Humana by 0.4% in the 3rd quarter. Capital Research Global Investors now owns 2,590,534 shares of the insurance provider’s stock valued at $1,008,129,000 after acquiring an additional 11,466 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Humana by 4.5% in the 3rd quarter. Janus Henderson Group PLC now owns 1,615,830 shares of the insurance provider’s stock valued at $628,791,000 after acquiring an additional 69,820 shares in the last quarter. Finally, CI Investments Inc. raised its holdings in Humana by 36.6% in the 3rd quarter. CI Investments Inc. now owns 1,044,038 shares of the insurance provider’s stock valued at $406,287,000 after acquiring an additional 279,480 shares in the last quarter. 92.96% of the stock is owned by hedge funds and other institutional investors.

NYSE:HUM traded down $14.43 on Friday, hitting $444.56. 986,508 shares of the stock were exchanged, compared to its average volume of 939,125. The stock has a market capitalization of $56.34 billion, a price-to-earnings ratio of 18.86, a P/E/G ratio of 1.35 and a beta of 0.94. Humana Inc. has a 52 week low of $351.20 and a 52 week high of $475.44. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.62 and a current ratio of 1.53. The company’s 50-day moving average price is $440.69 and its 200 day moving average price is $435.16.

Humana (NYSE:HUMGet Rating) last announced its quarterly earnings data on Wednesday, April 27th. The insurance provider reported $8.04 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $6.79 by $1.25. The firm had revenue of $23.97 billion during the quarter, compared to analysts’ expectations of $23.54 billion. Humana had a return on equity of 17.27% and a net margin of 3.51%. The company’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same period in the previous year, the business posted $7.67 EPS. As a group, equities research analysts predict that Humana Inc. will post 24.51 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 29th. Shareholders of record on Thursday, June 30th will be issued a dividend of $0.7875 per share. The ex-dividend date is Wednesday, June 29th. This represents a $3.15 annualized dividend and a yield of 0.71%. Humana’s dividend payout ratio is currently 13.36%.

Several research firms have commented on HUM. BMO Capital Markets cut their price target on Humana from $490.00 to $415.00 in a report on Friday, January 7th. Deutsche Bank Aktiengesellschaft increased their target price on Humana from $418.00 to $435.00 in a report on Thursday, February 3rd. Mizuho reissued a “buy” rating and issued a $500.00 target price on shares of Humana in a report on Friday, January 7th. Truist Financial increased their target price on Humana from $460.00 to $490.00 in a report on Thursday, April 7th. Finally, Sanford C. Bernstein dropped their target price on Humana from $470.00 to $431.00 in a report on Tuesday, January 11th. Seven analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $486.28.

Humana Company Profile (Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMGet Rating).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.